{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T10:21:22Z","timestamp":1790936482271,"version":"4.1.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Microbiol Immunol"],"published-print":{"date-parts":[[2009,8]]},"DOI":"10.1007\/s00430-009-0117-6","type":"journal-article","created":{"date-parts":[[2009,6,5]],"date-time":"2009-06-05T23:45:07Z","timestamp":1244245507000},"page":"147-155","source":"Crossref","is-referenced-by-count":18,"title":["Human immunodeficiency virus: 25\u00a0years of diagnostic and therapeutic strategies and their impact on hepatitis B and C virus"],"prefix":"10.1007","volume":"198","author":[{"given":"Martin","family":"St\u00fcrmer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans Wilhelm","family":"Doerr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lutz","family":"G\u00fcrtler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,6,4]]},"reference":[{"key":"117_CR1","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJM198112103052401","volume":"305","author":"MD Gottlieb","year":"1981","unstructured":"Gottlieb MD, Schroff R, Schanker HM, Weissman JD, Fan PT, Wolf RA, Saxon A (1981) Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men. N Engl J Med 305:1425\u20131431","journal-title":"N Engl J Med"},{"key":"117_CR2","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1126\/science.6189183","volume":"220","author":"F Barr\u00e9-Sinoussi","year":"1983","unstructured":"Barr\u00e9-Sinoussi F, Chermann JC, Rey F, Nugeyre MT, Chamaret S, Gruest J, Dauguet C, Axler-Blin C, V\u00e9zinet-Brun F, Rouzioux C, Rozenbaum W, Montagnier L (1983) Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 220:868\u2013871. doi: 10.1126\/science.6189183","journal-title":"Science"},{"key":"117_CR3","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1126\/science.6601823","volume":"220","author":"RC Gallo","year":"1983","unstructured":"Gallo RC, Sarin PS, Gelmann EP, Robert-Guroff M, Richardson E, Kalyanaraman VS, Mann D, Sidhu GD, Stahl RE, Zolla-Pazner S, Leibowitch J, Popovic M (1983) Isolation of human T-cell leukemia virus in acquired immune deficiency syndrome (AIDS). Science 220:865\u2013867. doi: 10.1126\/science.6601823","journal-title":"Science"},{"key":"117_CR4","doi-asserted-by":"crossref","DOI":"10.1128\/9781555815653","volume-title":"HIV and the pathogensis of AIDS","author":"JA Levy","year":"2007","unstructured":"Levy JA (2007) HIV and the pathogensis of AIDS, 3rd edn. ASM Press, Washington DC","edition":"3"},{"key":"117_CR5","volume-title":"The call of the wild: what can be learned from studies of SIV infection in natural hosts. HIV Seq Compendium 2005:2\u201329","author":"S Gordon","year":"2005","unstructured":"Gordon S, Pandrea I, Dunham R, Apretei C, Silvestri G (2005) The call of the wild: what can be learned from studies of SIV infection in natural hosts. HIV Seq Compendium 2005:2\u201329. Los Alamos, New Mexico"},{"key":"117_CR6","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1126\/science.7939718","volume":"266","author":"SW Barnett","year":"1994","unstructured":"Barnett SW, Murthy KK, Herndier BG, Levy JA (1994) An AIDS like condition induced in baboons by HIV-2. Science 266:642\u2013646. doi: 10.1126\/science.7939718","journal-title":"Science"},{"key":"117_CR7","doi-asserted-by":"crossref","first-page":"10256","DOI":"10.1128\/JVI.76.20.10256-10263.2002","volume":"76","author":"R Onaga","year":"2002","unstructured":"Onaga R, Kornfeld C, Pandrea I, Estaquier J, Souqui\u00e8re S, Rouquet P, Apetrei C, Poques P, M\u00fcller-Trutwin MC (2002) High levels of viral replication contrast with only transient changes in CD4+ and CD8+ cell numbers during the early phase of experimental infection with simian immunodeficiency virus SIVmnd-1 in Mandrillus sphinx. J Virol 76:10256\u201310263. doi: 10.1128\/JVI.76.20.10256-10263.2002","journal-title":"J Virol"},{"key":"117_CR8","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/444164a","volume":"444","author":"F Heuerswyn Van","year":"2006","unstructured":"Van Heuerswyn F, Li Y, Neel C, Bailess E, Keele BF, Liu W, Loul S, Butel C, Liegeois F, Bienvenue Y, Ngolle EM, Sharp PM, Shaw GM, Delaporte E, Hahn BH, Peeters M (2006) SIV infection in wild gorillas. Nature 444:164. doi: 10.1038\/444164a","journal-title":"Nature"},{"key":"117_CR9","first-page":"309","volume":"42","author":"AP Fleming","year":"1988","unstructured":"Fleming AP (1988) Seroepidemiology of human immunodeficiency viruses in Africa. Biomed Pharmacother 42:309\u2013320","journal-title":"Biomed Pharmacother"},{"key":"117_CR10","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/nature07390","volume":"455","author":"M Worobey","year":"2008","unstructured":"Worobey M, Gemmel M, Teuwen DE, Haselkorn T, Kunstman K, Bunce M, Muyembe JJ, Kabongo JMM, Kalengayi RM, Van Marck E, Gilbert MT, Wolinsky SM (2008) Direct evidence of extensive diversity of HIV-1 in Kinshasa by 1960. Nature 455:661\u2013664. doi: 10.1038\/nature07390","journal-title":"Nature"},{"key":"117_CR11","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/BF00191943","volume":"182","author":"PM Ndumbe","year":"1993","unstructured":"Ndumbe PM, Atchou G, Biwole M, Lobe V, Ayuk-Takem J (1993) Infections among pygmies in the Eastern province of Cameroon. Med Microbiol Immunol (Berl) 182:281\u2013284. doi: 10.1007\/BF00191943","journal-title":"Med Microbiol Immunol (Berl)"},{"key":"117_CR12","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/455605a","volume":"455","author":"PM Sharp","year":"2008","unstructured":"Sharp PM, Hahn BH (2008) Prehistory of HIV-1. Nature 455:605\u2013606. doi: 10.1038\/455605a","journal-title":"Nature"},{"key":"117_CR13","volume-title":"HIV-1 subtype and circulating recombinant form (CRF), references sequences, 2005. HIV Seq Compendium 2005:41\u201348","author":"T Leitner","year":"2005","unstructured":"Leitner T, Korber B, Daniels M, Calef C, Foley B (2005) HIV-1 subtype and circulating recombinant form (CRF), references sequences, 2005. HIV Seq Compendium 2005:41\u201348. Los Alamos, New Mexico"},{"key":"117_CR14","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1097\/01.aids.0000247564.73009.bc","volume":"20","author":"J Hemelaar","year":"2006","unstructured":"Hemelaar J, Gouws E, Ghys PD, Osmanov S (2006) Global and regional distribution of HIV-1 genetic subtypes in 2004. AIDS 20:2011\u20132019. doi: 10.1097\/01.aids.0000247564.73009.bc","journal-title":"AIDS"},{"key":"117_CR15","doi-asserted-by":"crossref","first-page":"12523","DOI":"10.1128\/JVI.77.23.12523-12534.2003","volume":"77","author":"V Courgnaud","year":"2003","unstructured":"Courgnaud V, Abela B, Pourrut X, Mpoudi-Ngolle E, Loul S, Delaporte E, Peeters M (2003) Identification of a new simiam immunodeficiency lineage with a vpu gene present among different cercopithecus monkeys (C. mona, C. cephus, and C. nictitans) from Cameroon. J Virol 77:12523\u201312534. doi: 10.1128\/JVI.77.23.12523-12534.2003","journal-title":"J Virol"},{"key":"117_CR16","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1089\/aid.2007.0071","volume":"23","author":"T Leitner","year":"2007","unstructured":"Leitner T, Dazza MC, Ekwalanga M, Apetrei C, Saragosti S (2007) Sequence diversity among chimpanzee immunodeficiency viruses (SIVcpz) suggests that SIVcpzPts was derived from SIVcpzPtt through additional recombination events. AIDS Res Hum Retroviruses 23:1114\u20131118. doi: 10.1089\/aid.2007.0071","journal-title":"AIDS Res Hum Retroviruses"},{"key":"117_CR17","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1128\/JVI.79.2.1312-1319.2005","volume":"79","author":"E Nerrienet","year":"2005","unstructured":"Nerrienet E, Santiago ML, Foupouapuognini Y, Bailes E, Mundy NI, Njinku B, Kfutwah A, Muller-Trutwin MC, Barre-Sinoussi F, Shaw GM, Sharp PM, Hahn BH, Ayouba A (2005) Simian immunodeficiency virus infection in wild caught chimpanzees from Cameroon. J Virol 79:1312\u20131319. doi: 10.1128\/JVI.79.2.1312-1319.2005","journal-title":"J Virol"},{"key":"117_CR18","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.virol.2007.06.018","volume":"368","author":"F Heuverswyn Van","year":"2007","unstructured":"Van Heuverswyn F, Yingying LI, Bailes E, Neel C, Lafay B, Keele BF, Shaw KS, Takehisa J, Kraus MH, Loul S, Butel C, Liegeois F, Yangda B, Sharp PM, Mpoudi-Ngolle E, Delaporte E, Hahn BH, Peeters M (2007) Genetic diversity and phylogeographic clustering of SIVcpzPtt in wild chimpanzees in Cameroon. Virology 368:155\u2013171. doi: 10.1016\/j.virol.2007.06.018","journal-title":"Virology"},{"issue":"Suppl 3","key":"117_CR19","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1097\/01.aids.0000327510.68503.e8","volume":"22","author":"T Quinn","year":"2008","unstructured":"Quinn T (2008) HIV epidemiology and the effects of antiviral therapy on long-term consequences. AIDS 22(Suppl 3):S7\u2013S12. doi: 10.1097\/01.aids.0000327510.68503.e8","journal-title":"AIDS"},{"key":"117_CR20","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/BF00190533","volume":"176","author":"I Wendler","year":"1987","unstructured":"Wendler I, Jentsch KD, Schneider J, Hunsmann G (1987) Efficient replication of HTLV-III and STLV-III mac in human Jurkat cells. Med Microbiol Immunol (Berl) 176:273\u2013280. doi: 10.1007\/BF00190533","journal-title":"Med Microbiol Immunol (Berl)"},{"key":"117_CR21","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/BF02123869","volume":"175","author":"H Nakashima","year":"1986","unstructured":"Nakashima H, Koyanagi Y, Harada S, Yamamoto N (1986) Effect of HTLV-III on the macromolecular synthesis in HTLV-I carrying cell line MT-4. Med Microbiol Immunol (Berl) 175:325\u2013334. doi: 10.1007\/BF02123869","journal-title":"Med Microbiol Immunol (Berl)"},{"key":"117_CR22","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1128\/JCM.02196-07","volume":"46","author":"SM Owen","year":"2008","unstructured":"Owen SM, Yang C, Spira T, Ou CY, Pau CP, Parekh BS, Candal D, Kuehl D, Kennedy MS, Rudolph D, Low W, Delatorre N, Masciotra S, Kalish ML, Cowart F, Barnett T, Lal R, McDougal JS (2008) Alternative algorithm for human immunodeficiency virus infection diagnosis using tests that are licensed in United States. J Clin Microbiol 46:1588\u20131595. doi: 10.1128\/JCM.02196-07","journal-title":"J Clin Microbiol"},{"key":"117_CR23","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1128\/JCM.37.6.1802-1808.1999","volume":"37","author":"K Ayoagi","year":"1999","unstructured":"Ayoagi K, Ohue C, Iida K, Kimura T, Tanaka E, Kiyosawa K, Yagi S (1999) Development of a single and highly sensitive enzyme immunoassay for hepatitis C virus core antigen. J Clin Microbiol 37:1802\u20131808","journal-title":"J Clin Microbiol"},{"key":"117_CR24","doi-asserted-by":"crossref","first-page":"3212","DOI":"10.1128\/JCM.41.7.3212-3220.2003","volume":"41","author":"P Veillon","year":"2003","unstructured":"Veillon P, Payan C, Picchio G, Montreuil MM, Guntz P, Lunel F (2003) Comparative evaluation of the total hepatitis C virus core antigen, branched-DNA, and Amplicor Monitor assay in determining viremia for patients with chronic hepatitis C during interferon plus ribavirin combination therapy. J Clin Microbiol 41:3212\u20133220. doi: 10.1128\/JCM.41.7.3212-3220.2003","journal-title":"J Clin Microbiol"},{"key":"117_CR25","first-page":"135","volume":"53","author":"F Rouet","year":"2007","unstructured":"Rouet F, Rouzioux C (2007) The measurement of HIV-1 viral load in resource limited settings: how and where? Clin Lab (Zaragoza) 53:135\u2013148","journal-title":"Clin Lab (Zaragoza)"},{"key":"117_CR26","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1128\/JCM.02385-06","volume":"45","author":"M Schutten","year":"2007","unstructured":"Schutten M, Peters D, Back NK, Beuselinck K, Foulongne V, Gerreti AM, Pandiani L, Tiemann C, Niesters HG (2007) Multicenter evaluation of the new Abbott Real Time assays for quantitative detection of human immunodeficiency virus type 1 and hepatitis C virus RNA. J Clin Microbiol 45:1712\u20131717. doi: 10.1128\/JCM.02385-06","journal-title":"J Clin Microbiol"},{"key":"117_CR27","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0166-0934(99)00028-2","volume":"80","author":"JJ Lefrere","year":"1999","unstructured":"Lefrere JJ, Coste J, Defer C, Mercier B, Loisseau P, Vignon D, Pawlotsky JM, Biagini P, Lerable J, Rouger P, Roudot-Thoraval F, Ferec C (1999) Screening for HBV, HCV and HIV genomes in blood donations: shortcomings of pooling revealed by a multicentre study simulating real-time testing. J Virol Methods 80:33\u201344. doi: 10.1016\/S0166-0934(99)00028-2","journal-title":"J Virol Methods"},{"key":"117_CR28","doi-asserted-by":"crossref","first-page":"8","DOI":"10.2807\/esm.10.02.00522-en","volume":"10","author":"R Offergeld","year":"2005","unstructured":"Offergeld R, Faensen D, Ritter S, Hamouda O (2005) Human immunodeficiency virus, hepatitis C and B infections among blood donors in Germany 2000\u20132002: risk of virus transmission and the impact of nucleic acid amplification testing. Euro Surveill 10:8\u201311","journal-title":"Euro Surveill"},{"key":"117_CR29","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1086\/589297","volume":"47","author":"MS Hirsch","year":"2008","unstructured":"Hirsch MS, G\u00fcnthard HF, Schapiro JM, Brun-V\u00e9zinet F, Clotet B, Hammer SM, Johnson VA, Kunitzkes DR, Mellors JW, Pillay D, Yeni PG, Jacobsen DM, Richman DD (2008) Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendation of the International AIDS society\u2014USA panel. Clin Infect Dis 47:266\u2013285. doi: 10.1086\/589297","journal-title":"Clin Infect Dis"},{"key":"117_CR30","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S1386-6532(01)00156-1","volume":"22","author":"M Arens","year":"2001","unstructured":"Arens M (2001) Clinically relevant sequence-based genotyping of HBV, HCV, CMV and HIV. J Clin Virol 22:11\u201329. doi: 10.1016\/S1386-6532(01)00156-1","journal-title":"J Clin Virol"},{"key":"117_CR31","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1002\/jmv.21191","volume":"80","author":"SJ Klug","year":"2008","unstructured":"Klug SJ, Molijn A, Schopp B, Holz B, Iftner A, Quint WJF, Snijders P, Petry KU, Krueger Kjaer S, Munk C, Iftner T (2008) Comparison of the performance of different HPV genotyping methods for detection genital HPV types. J Med Virol 80:1264\u20131274. doi: 10.1002\/jmv.21191","journal-title":"J Med Virol"},{"key":"117_CR32","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s00430-007-0048-z","volume":"196","author":"J Cinatl","year":"2007","unstructured":"Cinatl J, Michaelis M, Doerr HW (2007) The threat of avian influenza (H5N1). Part III: antiviral therapy. Med Microbiol Immunol (Berl) 196:203\u2013212. doi: 10.1007\/s00430-007-0048-z","journal-title":"Med Microbiol Immunol (Berl)"},{"key":"117_CR33","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1097\/01.aids.0000161768.98534.e7","volume":"19","author":"JC Plantier","year":"2005","unstructured":"Plantier JC, Dachraoui R, Lemee V, Guedin M, Borsa-Lebas F, Caron F, Simon F (2005) HIV-1 resistance genotyping on dried serum spots. AIDS 19:391\u2013397. doi: 10.1097\/01.aids.0000161768.98534.e7","journal-title":"AIDS"},{"key":"117_CR34","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s00430-007-0066-x","volume":"197","author":"M Ho","year":"2008","unstructured":"Ho M (2008) The history of cytomegalovirus and its disease. Med Microbiol Immunol (Berl) 197:65\u201373. doi: 10.1007\/s00430-007-0066-x","journal-title":"Med Microbiol Immunol (Berl)"},{"key":"117_CR35","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1038\/nrd2424","volume":"12","author":"E DeClercq","year":"2007","unstructured":"DeClercq E (2007) The design of drugs for HIV and HCV. Nat Rev Drug Discov 12:1001\u20131018. doi: 10.1038\/nrd2424","journal-title":"Nat Rev Drug Discov"},{"key":"117_CR36","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1177\/135965350801300313","volume":"13","author":"RD Sloan","year":"2008","unstructured":"Sloan RD, Ijaz S, Moore PL, Harrison TJ, Teo CG, Tedder RS (2008) Antiviral resistance mutations potentiate hepatitis B virus immune evasion through disruption of its surface antigen a determinant. Antivir Ther 13:439\u2013447","journal-title":"Antivir Ther"},{"key":"117_CR37","doi-asserted-by":"crossref","first-page":"3617","DOI":"10.1128\/AAC.00654-08","volume":"52","author":"B Menne","year":"2008","unstructured":"Menne B, Butter SD, George AL, Tochkov IA, Zhu Y, Xiong S, Gerin JL, Cote PJ, Tennant BC (2008) Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection. Antimicrob Agents Chemother 52:3617\u20133632. doi: 10.1128\/AAC.00654-08","journal-title":"Antimicrob Agents Chemother"},{"key":"117_CR38","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/nrd2411","volume":"12","author":"MP Manns","year":"2007","unstructured":"Manns MP, Foster GR, Rockstroh JK, Zeuzem S, Zoulim F, Houghton M (2007) The way forward in HCV treatment\u2014finding the right path. Nat Rev Drug Discov 12:991\u20131000. doi: 10.1038\/nrd2411","journal-title":"Nat Rev Drug Discov"},{"key":"117_CR39","doi-asserted-by":"crossref","first-page":"2937","DOI":"10.1210\/jc.2008-1019","volume":"93","author":"TT Brown","year":"2008","unstructured":"Brown TT (2008) Approach to the human immunodeficiency virus-infected patient with lipodystrophy. J Clin Endocrinol Metab 93:2937\u20132945. doi: 10.1210\/jc.2008-1019","journal-title":"J Clin Endocrinol Metab"},{"key":"117_CR40","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ijantimicag.2005.04.003","volume":"26","author":"D Savoia","year":"2005","unstructured":"Savoia D, Allice T, Tovo PA (2005) Antileishmanial activity of HIV protease inhibitors. Int J Antimicrob Agents 26:92\u201394. doi: 10.1016\/j.ijantimicag.2005.04.003","journal-title":"Int J Antimicrob Agents"},{"key":"117_CR41","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1086\/592280","volume":"198","author":"N Trudel","year":"2008","unstructured":"Trudel N, Garg R, Messier N, Sundar S, Ouellette M, Tremblay MJ (2008) Intracellular survival of Leishmania species that cause visceral leishmaniasis is significantly reduced by HIV-1 protease inhibitors. J Infect Dis 198:1292\u20131299. doi: 10.1086\/592280","journal-title":"J Infect Dis"},{"key":"117_CR42","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1128\/AAC.01149-07","volume":"52","author":"Y He","year":"2008","unstructured":"He Y, King MS, Kempf DJ, Lu L, Lim HB, Krishnan P, Kati W, Middleton T, Molla A (2008) Relative replication capacity and selective advantage profiles of protease inhibitor-resistant hepatitis C virus (HCV) NS3 protease mutants in the HCV genotype 1b replicon system. Antimicrob Agents Chemother 52:1101\u20131110. doi: 10.1128\/AAC.01149-07","journal-title":"Antimicrob Agents Chemother"},{"key":"117_CR43","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1002\/hep.21774","volume":"46","author":"N Forestier","year":"2007","unstructured":"Forestier N, Reesink HW, Weegink CJ, McNair L, Kieffer TL, Chu HM, Purdy S, Jansen PL, Zeuzem S (2007) Antiviral activity of telaprevir (VX-950) and peginterferon-2\u03b1 in patients with hepatitis C. Hepatology 46:640\u2013648. doi: 10.1002\/hep.21774","journal-title":"Hepatology"},{"key":"117_CR44","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1086\/595848","volume":"48","author":"V Soriano","year":"2009","unstructured":"Soriano V, Peters MG, Zeuzem S (2009) New therapies for hepatitis C virus infection. Clin Infect Dis 48:313\u2013320. doi: 10.1086\/595848","journal-title":"Clin Infect Dis"},{"key":"117_CR45","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S0140-6736(07)60597-2","volume":"369","author":"B Grinszteijn","year":"2007","unstructured":"Grinszteijn B, Nguyen BY, Katlama C, Gatell JM, Lazzarin A, Vittecoq D, Gonzalez CJ, Chen J, Harvey CM, Isaacs RD (2007) Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial. Lancet 369:1261\u20131269. doi: 10.1016\/S0140-6736(07)60597-2","journal-title":"Lancet"},{"key":"117_CR46","doi-asserted-by":"crossref","first-page":"4338","DOI":"10.1128\/AAC.01543-07","volume":"52","author":"M Iwamoto","year":"2008","unstructured":"Iwamoto M, Wenning LA, Petry AS, Laethem M, de Smet M, Kost JT, Breidinger SA, Mangin EC, Azrolan N, Greenberg HE, Haazen W, Stone JA, Gottesdiener KM, Wagner JA (2008) Minimal effects of ritonavir and efavirenz on the pharmacogenetic of raltegravir. Antimicrob Agents Chemother 52:4338\u20134343. doi: 10.1128\/AAC.01543-07","journal-title":"Antimicrob Agents Chemother"},{"key":"117_CR47","doi-asserted-by":"crossref","first-page":"2861","DOI":"10.1128\/AAC.00210-08","volume":"52","author":"A Hombrouck","year":"2008","unstructured":"Hombrouck A, Van Remoortel B, Michiels M, Noppe W, Christ F, Eneroth A, Sahlberg BL, Benkestock K, Vrang L, Johansson NG, Barecca ML, De Luca L, Ferro S, Chimirri A, Debyser Z, Witvrouw M (2008) Preclinical evaluation of 1H-benzylindole derivatives as novel human immunodeficiency virus integrase strand transfer inhibitors. Antimicrob Agents Chemother 52:2861\u20132869. doi: 10.1128\/AAC.00210-08","journal-title":"Antimicrob Agents Chemother"},{"key":"117_CR48","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1128\/AAC.01228-07","volume":"52","author":"I Malet","year":"2008","unstructured":"Malet I, Delelis O, Valentin MA, Montes B, Soulie C, Wirden M, Tchertanov L, Peytavin G, Reynes J, Mouscadet JF, Katlama C, Calvez V, Marcelin AG (2008) Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro. Antimicrob Agents Chemother 52:1351\u20131358. doi: 10.1128\/AAC.01228-07","journal-title":"Antimicrob Agents Chemother"},{"key":"117_CR49","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s11262-007-0098-8","volume":"35","author":"VA Morozov","year":"2007","unstructured":"Morozov VA, Morozov AV, Sch\u00fcrmann D, Jessen H, K\u00fccherer C (2007) Transmembrane protein polymorphism and resistance to T-20 (Enfurtide, Fuzeon) in HIV-1 infected therapy-naive seroconverters and AIDS patients under HAART-T-20 therapy. Virus Genes 35:167\u2013174. doi: 10.1007\/s11262-007-0098-8","journal-title":"Virus Genes"},{"key":"117_CR50","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1086\/589289","volume":"47","author":"RD Mac Arthur","year":"2008","unstructured":"Mac Arthur RD, Novak RM (2008) Reviews of anti-infective agents: maraviroc: the first of a new class of antiretroviral agents. Clin Infect Dis 47:236\u2013241. doi: 10.1086\/589289","journal-title":"Clin Infect Dis"},{"key":"117_CR51","doi-asserted-by":"crossref","first-page":"2937","DOI":"10.1097\/00002030-200012220-00016","volume":"14","author":"DR Briggs","year":"2000","unstructured":"Briggs DR, Tuttle DL, Sleasman JW, Goodenow MM (2000) Envelope V3 amino acid sequence predicts HIV-1 phenotype (co-receptor usage and tropism for macrophages). AIDS 14:2937\u20132939. doi: 10.1097\/00002030-200012220-00016","journal-title":"AIDS"},{"key":"117_CR52","first-page":"S65","volume":"12","author":"M Lewis","year":"2007","unstructured":"Lewis M, Simpson P, Fransen S, Huang W, Whitcomb J, Mosley M, Robertson DL, Mansfield R, Ciaramella G, Westby M (2007) CXCR4-using virus detected in patients receiving maraviroc in the Phase III studies MOTIVATE 1 and 2 originates from a pre-existing minority of CXCR4-using virus. Antivir Ther 12:S65","journal-title":"Antivir Ther"},{"key":"117_CR53","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJMoa0803152","volume":"359","author":"RM Gulick","year":"2008","unstructured":"Gulick RM, Lalezari J, Goodrich J, Clumeck N, De Jesus E, Horban A, Nadler J, Clotet B, Karlsson A, Wohlfeiler M, Montana JB, McHale M, Sullivan J, Ridgway C, Felstead S, Dunne MW, van der Ryst E, Mayer H, MOTIVATE study teams (2008) Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med 359:1429\u20131441. doi: 10.1056\/NEJMoa0803152","journal-title":"N Engl J Med"},{"key":"117_CR54","unstructured":"Lewis M, Simpson P, Whitcomb J, Li X, Robertson DL, Westby M (2008) Changes in V3 loop sequence associated with failure of maraviroc treatment in patients enrolled in the MOTIVATE 1 and 2 trials. In: 15th conference on retroviruses and opportunistic infections. Boston, 2008. Poster 871"},{"key":"117_CR55","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1128\/AAC.01650-08","volume":"53","author":"K Baelen Van","year":"2009","unstructured":"Van Baelen K, Salzwedel K, Rondelez E, Van Eygen V, De Vos S, Verheyen A, Steegen K, Verlinden Y, Allaway GP, Stuyver LJ (2009) Susceptibility of human immunodeficiency virus type 1 to the maturation inhibitor Bevirimat is modulated by baseline polymorphisms in gag spacer peptide 1. Antimicrob Agents Chemother 53:2185\u20132188. doi: 10.1128\/AAC.01650-08","journal-title":"Antimicrob Agents Chemother"},{"key":"117_CR56","doi-asserted-by":"crossref","first-page":"4884","DOI":"10.1128\/JVI.02659-08","volume":"83","author":"CS Adamson","year":"2009","unstructured":"Adamson CS, Waki K, Ablan SD, Salzwedel K, Freed EO (2009) Impact of human immunodeficiencyvirus type 1 resistance to protease inhibitors on evolution of resistance to the maturation inhibitor Bevirimat (PA-457). J Virol 83:4884\u20134894. doi: 10.1128\/JVI.02659-08","journal-title":"J Virol"},{"key":"117_CR57","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1038\/nrd2422","volume":"12","author":"EC Borden","year":"2007","unstructured":"Borden EC, Sen GC, Uze G, Silverman RH, Ransohoff RM, Foster GR, Stark GR (2007) Interferons at age 50: past, current and future impact on biomedicine. Nat Rev Drug Discov 12:975\u2013990. doi: 10.1038\/nrd2422","journal-title":"Nat Rev Drug Discov"},{"key":"117_CR58","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00430-006-0024-z","volume":"196","author":"A Goyal","year":"2007","unstructured":"Goyal A, Hofmann WP, Hermann E, Traver S, Hissar SS, Aroya N, Blum HE, Zeuzem S, Sarrazin C, Sarin SK (2007) The hepatitis C virus NS5A protein and response to interferon \u03b1: mutational analyses in patients with chronic HCV genotype 3a infection from India. Med Microbiol Immunol (Berl) 196:11\u201321. doi: 10.1007\/s00430-006-0024-z","journal-title":"Med Microbiol Immunol (Berl)"}],"container-title":["Medical Microbiology and Immunology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00430-009-0117-6.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T14:59:04Z","timestamp":1685026744000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00430-009-0117-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,6,4]]},"references-count":58,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,8]]}},"alternative-id":["117"],"URL":"https:\/\/doi.org\/10.1007\/s00430-009-0117-6","relation":{},"ISSN":["0300-8584","1432-1831"],"issn-type":[{"value":"0300-8584","type":"print"},{"value":"1432-1831","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,6,4]]}}}